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Abstract
Background Langerhans cell histiocytosis (LCH) is characterized by the proliferation of pathologic Langerhans cells.
The disease can develop in any age and can affect almost any organ. Cutaneous involvement is frequent in LCH. The
recent demonstration of the activating, oncogenic BRAFV600E gene mutation in LCH samples strongly supports the
neoplastic origin of the disease.
Objectives Our aim was to analyse the clinical data of the patients and whether BRAFV600E mutation is present in skin
lesions of patients with adult onset LCH, and to investigate whether the BRAFV600E mutation status has any effect on
the clinical presentation and the outcome of the disease.
Methods We diagnosed and treated 15 adult LCH patients in the period of 1987–2012 and collected their clinical data.
Three of our patients suffered from skin involvement and 12 patients had multiorgan disease (ﬁve patients out of the mul-
tisystem group died). Eleven formalin-ﬁxed parafﬁn-embedded skin samples from 10 patients were available for
BRAFV600E mutation analysis.
Results Among the 11 examined samples, 6 contained the BRAFV600E mutation (54.5%). Our results indicate that in
the adult group of LCH patients the presence of BRAFV600E mutation is similar to what was previously suggested in
case of the childhood forms, at least as far as skin lesions are concerned. The BRAF mutation status of our patients does
not seem to correlate with the extent and/or the outcome of the disease.
Conclusion Our results support the neoplastic origin of LCH and suggest that skin lesions of LCH are sufﬁcient for the
diagnosis of the disease and for assessing its BRAF status. In addition, analysis of BRAF status of patients with LCH can
lead to the administration of new targeted therapies which may provide better disease control and prognosis.
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Introduction
Langerhans cell histiocytosis (LCH) is characterized by the
proliferation of S100 protein, CD1a and Langerin-positive cells
containing electron-microscopically detectable Birbeck granules.
These cells resemble or are similar to epidermal antigen present-
ing dendritic Langerhans cells (LC) and thought to be derived
from haematopoietic, histiocytic precursors or from LCs.1–8
LCH is a rare disease, the incidence of childhood and adult
forms is estimated to 1-9 per million but the number of adult
cases is significantly lower.4,7–9 The clinical appearance of LCH
is highly variable, it can develop at any age and in almost any
organ. According to the recommendation of the ‘Histiocytic
Society’ LCH can be classified into three main forms depending
on the involved organs: single system disease and multisystem
disease with or without ‘risk organ’ (lung, liver, spleen, haemat-
opoietic) dysfunction.1,7–11
Cutaneous involvement is frequently present in LCH. Skin
manifestation is more common in children, but numerous adult
patients are also presented with skin lesions.9,12 As up to 30–
80% of LCH patients develop skin symptoms, the diagnosis is
frequently provided by histopathological examination of the
skin biopsy.1,7,12
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The prognosis depends on the dissemination of the disease,
the presence or absence of organ dysfunction, the patient’s age
of onset and the response to the initial therapy.
The aetiology and pathogenesis of the disease has not been
fully understood yet, and even the fact whether LCH is a true
malignant or a reactive, inflammatory process has been debated
in the literature.2–4,6–9 Recently, however, a new possible molec-
ular genetic background has been suggested with the demonstra-
tion of the activating, oncogenic BRAFV600E gene mutation in
a subset (38–68%) of LCH samples. This strongly supports the
neoplastic origin of the disease.2,3,5,6,13,14
Our first aim was to collect adult onset LCH patients and to
analyse the characteristics of their disease. The second goal of
our study was to detect the presence and rate of BRAFV600E
mutation solely from skin lesions. Previous literature data evalu-
ated the incidence of this mutation in all kinds of LCH lesions,
but among the analysed samples the ratio of skin lesion was rela-
tively low. Based on the presented data it can be estimated that
so far approximately not more than 30 skin samples were exam-
ined.3,5,13–15 As skin is a frequently involved organ and is an eas-
ily accessible site for biopsy to establish the histopathological
diagnosis of LCH patients it is very important to obtain data on
the availability of BRAF mutation status in such samples
too.1,7,12
Materials and methods
Patients and samples
Fifteen adult LCH patients were diagnosed and treated between
1987 and 2012 at the Department of Dermatology and Allergol-
ogy, Albert Szent-Gy€orgyi Clinical Center University of Szeged,
Hungary. Clinical and treatment characteristics of the patients
are summarized in Tables 1 and 2.
The available archived formalin-fixed paraffin-embedded
blocks were also retrieved. Eleven skin samples from 10 LCH
patients could be examined. One patient had two biopsies (a
punch biopsy and an excision) of the trunk’s skin in 1 month
interval to establish the diagnosis (Table 2). The other 5
patients’ skin samples were also examined at our department
earlier, but the samples originated from other laboratories and
the paraffin blocks were sent back after examination and were
not available for our current analysis.
BRAFV600 mutation detection
Five lm sections were obtained from formalin-fixed paraffin-
embedded tissue biopsy specimens. After deparaffinization
genomic DNA samples were isolated using the cobas DNA
Sample Preparation Kit (Roche Molecular Systems Inc.,
Roche Molecular Diagnostics, Branchburg, NJ, USA) accord-
ing to the users’ manual. BRAFV600E mutation was detected
on the cobas z 480 Analyzer with the cobas 4800 BRAF
V600 Mutation Test (Roche Molecular Systems Inc., Roche
Molecular Diagnostics) following the instructions of the
manufacturer.
Results
The development of skin symptoms drew the attention to the
underlying LCH in most of our 15 LCH patients. The male:
female ratio was 5:10 (1:2), the median age at the time of the
presentation of the skin lesions was 56 years (age range 24–
91 years). Three patients had single system disease, exhibiting
only skin symptoms, whereas 12 patients suffered from multisys-
tem disease with or without organ dysfunction. Diabetes insipi-
dus was present in six patients, the lymphoreticular system was
affected in nine cases and one patient had idiopathic thrombocy-
topenic purpura. Four patients had pulmonary involvement and
three patients developed bone lesions.
Most of the skin lesions were papules, plaques and nodules,
situated at the predilection sites. The flexural areas and the head
were involved in most cases and three patients suffered from
genital skin lesions. Thirteen patients had more than one
affected region. Pruritus, erosion and ulceration also compli-
cated the lesions very frequently (Fig. 1). Clinical data are shown
in Table 1. Diagnosis was confirmed by the examination of skin
biopsy specimens, showing the characteristic microscopic mor-
phology and the proliferation of CD1a positive cells (Fig. 2).
BRAF mutation detection was performed in 11 skin samples
from 10 LCH patients (patient no. 15 had two biopsies). Among
the 11 samples, 6 contained BRAFV600E mutation which repre-
sents 54.5%. Although the case number in our study is relatively
low and two BRAF positive biopsies came from one patient
(patient no. 15), we can conclude that approximately half of the
examined samples contained the mutation.
Two of our BRAF positive patients with multisystem disease
died. One of them died in spite of a combined therapy, whereas
the other patient refused treatment. The remaining three
patients positive for the examined BRAF mutation also had a
multisystem disease with organ dysfunction and they showed
significant improvement or became symptom free upon topical
and/or systemic steroid treatment and supportive therapy for
diabetes insipidus (Table 2, Fig. 3).
Two patients died of the disease in the BRAF negative group
suffering from the multisystem form of the disease. The remain-
ing three patients in the same group improved in response to the
treatment, even though two of them had multisystem involve-
ment with organ dysfunction, whereas the third patient had a
single system disease affecting only the skin. Although our case
number is too low to draw statistical conclusions, our observa-
tions strongly suggest that the BRAF mutation status may not
correlate with the extent and/or the outcome of this disease.
Discussion
The clinical manifestation of LCH is highly variable. Almost any
organ can be involved and the disease can develop at any age.
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Childhood cases are thought to have a tendency to be multisys-
tem disease, whereas adult patients are more prone to develop a
single system disease, although there are some controversies in
the literature concerning these data.1
The most frequently involved organs are the bone (which is
also the most common site of the single system disease), skin,
pituitary gland (leading to the development of diabetes insipi-
dus), liver, spleen, lung, bone marrow.1,7,9
Cutaneous involvement can be frequently present in the
affected individuals. According to the available literature, 30–
80% of the patients develop skin symptoms and it is often the
skin biopsy that provides the histopathological diagnosis.1,7,12
Although skin manifestation is more common in children, adult
forms can be presented also with skin lesions. These symptoms
can affect any part of the body but typically involve flexural, gen-
ital, perianal and glabrous areas. Papules, plaques, eczema-like
or seborrhoeic dermatitis-like rash with scales and scab along
with pruritus are the most common skin manifestations.9,12
Adult forms are almost similar to the childhood ones, but the
single lung involvement seems more frequent (up to 20–30%) in
adults. The isolated pulmonary disease is strongly associated
with smoking and polyclonal LCs can be detected in these
lesions quite frequently.4,7
The prognosis of LCH depends on its dissemination, the pres-
ence or absence of organ dysfunction, the patient’s age at disease
onset and the response to initial therapy.1,7,8 Patients with wide-
spread, high-risk disease have poor prognosis with a 20–50%
mortality rate in spite of combined therapy,2,3,7,8,16 and the
5-year event free survival ratio of adult forms is much better
even in the disseminated forms.7 Treatment of LCH depends
mainly on the dissemination of the disease. Single system disease
– mainly bone lesions – frequently requires surgical removal
(curettage) maybe combined with intralesional steroids while
multisystem forms, even with organ dysfunction needs com-
bined chemotherapy (vinblastine, methotrexate) and/or predni-
son.1,4,7–9,16 Localized cutaneous lesions can be treated with
topical steroid or tacrolimus while disseminated skin disease can
improve upon thalidomide, interferon, PUVA or methotrexate
and chemotherapy.7,9,10 Treatment of LCH in adults is more
challenging than in childhood because experience is more lim-
ited due to the low incidence in this age group.16
The aetiology and exact pathogenesis of this disease is still
not fully understood. It has been debated in the literature
whether LCH is a true malignant or a reactive, inflammatory
process.2–4, 6–9 It has been suggested that LCH is a clonal dis-
ease although there is a significant inflammatory component
in the infiltrate (eosinophils, macrophages, lymphocytes, giant
cells) with elevated levels of cytokines and chemokines.3,4,9
The recent demonstration of the activating, oncogenic
BRAFV600E gene mutation in 38–68% of LCH samples and the
fact that the neoplastic LC cases often carry this mutation
strongly supports the neoplastic origin of the disease.2,3,5,6,13,14T
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Recent data suggest that there is an activation of the RAS-RAF-
MEK pathway in the background of LCH but in BRAF negative
cases, however, the precise activating factors are not known
yet.4,6,9 Better understanding of the molecular background of the
disease is very important because in disseminated and treatment
refractory cases the possibility of a new targeted therapy based
on molecular pathology can be a promising option in the thera-
peutic repertoire. It has also been demonstrated that among
Table 2 BRAF mutation status of 11 lesions from 10 patients with their disease type, treatment modalities and outcomes
Patient no. BRAF mutation Multisystem disease Treatment Outcome
5 No Yes, with organ dysfunction Topical and systemic steroid, cytostatic drugs Deceased
6 Yes Yes, with organ dysfunction Topical and systemic steroid, cytostatic drugs Deceased
7 No Yes PUVA Deceased
8 Yes Yes, with organ dysfunction Topical and systemic steroid Improved
9 No Yes, with organ dysfunction Systemic steroid, cytostatic drugs Improved
10 No Yes, with organ dysfunction Topical steroid, cytostatic drugs Improved
11 Yes Yes, with organ dysfunction Topical and systemic steroid Improved
12 Yes Yes, with organ dysfunction Topical steroid Improved
14 No No Topical and systemic steroid, cytostatic drugs Improved
15 (2 bx) Yes
Yes
Yes, with organ dysfunction No treatment Deceased
Patient no. refers to patient’s numbers in Table 1.
(a)
(c)
(b)
Figure 1 Various skin lesions in LCH: (a)
erythematous plaques on the trunk – Patient
10, (b) erosions on the vulva – Patient 8, (c)
scaling papules and plaques on the nose –
Patient 13 (for patient numbers, refer
Table 1).
(a) (b)
Figure 2 The characteristic
histopathological picture of skin lesion in
LCH – Patient 15 (a) HE, (b) CD1a staining.
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other histiocytic disorders (both neoplastic and reactive
conditions) only nearly half of Erdheim-Chester diseases carry
the same BRAF mutation.13 There is even a recent report on
effective vemurafenib treatment in disseminated combined
Erdheim-Chester disease and LCH carrying the BRAFV600E
mutation.15,17,18
In the present work we were able to prove the presence of the
BRAFV600E mutation in 6 among 11 LCH skin samples
(54.5%). The frequency of BRAFV600E mutation in our series
correlates well with the initial data of Badalian-Very et co-work-
ers (57%)3 and the recent study of Satoh and his colleagues
(68%),14 whereas was higher than the results demonstrated by
two other authors’ Sahm5 and Haroche and their groups
(38%).13
It should be also emphasized that the previous studies analy-
sed the BRAF mutation status from lesions of various anatomical
sites (bone, lung, etc.) and only a few cutaneous lesions were
involved in these studies. Ours is the first one that was focusing
especially to skin LCH lesions. Taking into account the literature
data of 57% BRAF positivity in various LCH lesions3, our results
strongly suggest that skin lesions of LCH are eligible for the diag-
nosis of the disease and for the assessment of the BRAF mutation
status, too. Knowing the high proportion of skin involvement in
LCH patients this observation highlights the importance of skin
biopsy as an easily accessible diagnostic material.
According to the previous data it was suspected that the pres-
ence of this particular BRAF mutation might correlate with
younger age,3,4,19 but another studies could not prove this
hypothesis.14 The results on our adult group of LCH patient,
however, strongly suggest that the occurrence of BRAFV600E
mutation can be as frequent in childhood as in the adult forms
at least as far as skin lesions are concerned. Although the case
number in our study is too low to make statistical analysis, our
observations also suggest that the BRAF mutation status may
not present a clear correlation with the extent and/or the out-
come of the disease.
Conclusion
Our results support the neoplastic origin of LCH and correlates
well with the previous data on BRAFV600E mutation ratio in
this rare disease. These data suggest that the occurrence of the
mutation in adult forms can be as frequent as in childhood cases,
and underline the importance of the early recognition of skin
symptoms and the high impact of skin biopsy in the diagnosis of
the disease. Currently it is not clear whether the carriage of the
BRAF mutation has any effect on the extent and/or the outcome
of the disease, and further studies are required to answer these
questions. However, our results underlie the importance of
molecular pathway analyses that can potentially lead to the
administration of promising new targeted therapies in affected
individuals, providing better disease control and prognosis for
the LCH patients.15
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